Cardioselective beta1-blocker without internal sympathomimetic activity.
Has a weak membrane-stabilizing activity.
Has a hypotensive effect associated with a decrease in cardiac output and a decrease in peripheral vascular sympathetic stimulation.
When used in therapeutic doses, it does not have a cardiodepressive effect, does not affect glucose metabolism, does not reduce the bronchodilatory effects of beta-adrenergic agonists, and does not cause sodium retention in the body.
Valid for a long time.
Topical application in the form of eye drops lowers increased intraocular pressure.
The resorptive effect is negligible.
Open-angle glaucoma, intraocular hypertension, condition after laser trabeculoplasty, prolonged hypotensive therapy after surgical ophthalmologic intervention.
When applied topically, side effects characteristic of systemic use may be observed. During the period of use of the drug should not wear contact lenses.
Does not affect the size of the pupil, with angle-closure glaucoma, use only in combination with myotics.
When a patient is transferred to betaxolol after treatment with several anti-glaucoma drugs, the latter are gradually canceled.
During pregnancy and lactation, it is used in cases where the benefit outweighs the risk of side effects.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
Dosage and Administration
Topically. Buried in a conjunctival sac, 1 cap. 2 times a day
during the first month of treatment is carried out under the control of intraocular pressure.
Local: allergic reactions, eye discomfort, lacrimation, flushing of the skin, conjunctival itching, keratitis, anisocoria, photophobia.
Systemic: insomnia, depressive neurosis.
Terms of delivery from
for Adults on purpose doctor
Moscow Endocrine Plant, Russia